Mitsubishi UFJ Trust & Banking Corp decreased its position in shares of Agios Pharmaceuticals Inc (NASDAQ:AGIO) by 1.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 238,050 shares of the biopharmaceutical company’s stock after selling 4,360 shares during the period. Mitsubishi UFJ Trust & Banking Corp’s holdings in Agios Pharmaceuticals were worth $18,358,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Tiverton Asset Management LLC acquired a new position in Agios Pharmaceuticals during the 2nd quarter worth about $142,000. Rockefeller Capital Management L.P. acquired a new stake in Agios Pharmaceuticals in the 3rd quarter valued at about $134,000. Strs Ohio acquired a new stake in Agios Pharmaceuticals in the 2nd quarter valued at about $179,000. Barrett Asset Management LLC acquired a new stake in Agios Pharmaceuticals in the 2nd quarter valued at about $253,000. Finally, MML Investors Services LLC acquired a new stake in Agios Pharmaceuticals in the 3rd quarter valued at about $255,000. 94.93% of the stock is currently owned by hedge funds and other institutional investors.
A number of equities research analysts have issued reports on AGIO shares. Cann reaffirmed a “hold” rating on shares of Agios Pharmaceuticals in a research report on Wednesday, September 5th. Leerink Swann started coverage on Agios Pharmaceuticals in a research report on Monday, September 24th. They issued a “market perform” rating and a $80.00 price target on the stock. ValuEngine lowered Agios Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, September 11th. BidaskClub lowered Agios Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, September 19th. Finally, Guggenheim started coverage on Agios Pharmaceuticals in a research report on Monday, September 17th. They issued a “neutral” rating on the stock. Six investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. Agios Pharmaceuticals has an average rating of “Buy” and an average target price of $96.27.
Agios Pharmaceuticals (NASDAQ:AGIO) last issued its earnings results on Thursday, November 1st. The biopharmaceutical company reported ($1.63) earnings per share for the quarter, missing the consensus estimate of ($1.62) by ($0.01). Agios Pharmaceuticals had a negative return on equity of 48.51% and a negative net margin of 461.78%. The business had revenue of $15.20 million for the quarter, compared to analyst estimates of $22.72 million. During the same period last year, the business posted ($1.59) EPS. Agios Pharmaceuticals’s revenue was up 33.8% on a year-over-year basis. As a group, research analysts predict that Agios Pharmaceuticals Inc will post -6.12 earnings per share for the current year.
In other news, Director John Maraganore sold 13,555 shares of the firm’s stock in a transaction dated Tuesday, September 11th. The stock was sold at an average price of $72.75, for a total transaction of $986,126.25. Following the sale, the director now owns 38,609 shares of the company’s stock, valued at approximately $2,808,804.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Scott Biller sold 3,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 5th. The stock was sold at an average price of $83.07, for a total value of $249,210.00. Following the transaction, the insider now owns 60,196 shares in the company, valued at approximately $5,000,481.72. The disclosure for this sale can be found here. Insiders have sold a total of 22,555 shares of company stock worth $1,653,776 in the last three months. Corporate insiders own 3.02% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Mitsubishi UFJ Trust & Banking Corp Decreases Position in Agios Pharmaceuticals Inc (AGIO)” was first posted by Community Financial News and is the property of of Community Financial News. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece of content can be accessed at https://www.com-unik.info/2018/12/02/mitsubishi-ufj-trust-banking-corp-decreases-position-in-agios-pharmaceuticals-inc-agio.html.
Agios Pharmaceuticals Profile
Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.
Read More: Analyzing a company’s cash flow statement
Want to see what other hedge funds are holding AGIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agios Pharmaceuticals Inc (NASDAQ:AGIO).
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.